Form 4: Relay Therapeutics CEO Acquires 1.1 Million Stock Options
SEC Form 4 Filing
Relay Therapeutics CEO, Sanjiv Patel, was granted 1.1 million stock options on January 10, 2025, which vest quarterly over four years.
Summary
- Sanjiv Patel, the President and CEO of Relay Therapeutics, acquired 1,105,000 stock options on January 10, 2025.
- These options have an exercise price of $4.45 per share.
- The options vest in 16 equal quarterly installments starting after January 10, 2025, contingent on Mr. Patel's continued employment with the company.
- The options expire on January 9, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of Relay Therapeutics' stock price.
- If the CEO leaves the company before the options fully vest, he may forfeit some or all of the options.
Future Outlook
The stock options will vest over the next four years, subject to the CEO's continued employment.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of 16 equal quarterly installments is a typical approach to incentivize long-term performance.
- The exercise price of $4.45 is dependent on the current market price of the stock and the company's valuation.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of the stock option grant. |
| 01/10/2025 | Start date for the quarterly vesting of the stock options. |
| 01/09/2035 | Expiration date of the stock options. |
| 01/14/2025 | Date the form was signed. |
Keywords
stock options, executive compensation, insider trading, Sanjiv Patel, Relay Therapeutics, RLAY
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.